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1. Introduction 
In 1948, the US rheumatologist Philip Hench and his associates at the Mayo Clinic first 
administered hydrocortisone to a patient with rheumatoid arthritis and discovered its 
clinical benefits [1]. Two years later, Hench, together with biochemists Edward Kendall and 
Tadeus Reichstein, shared the Nobel Prize in Medicine. Today, glucocorticoids are among 
the most frequently prescribed class of anti-inflammatory medications [2]. They are part of 
the standard treatment for a wide range of disorders which feature inflammation and/or 
immune activation, such as asthma, chronic obstructive pulmonary disease, hypersensitivity 
reactions, autoimmune diseases, and in organ transplantation. However, even early on, the 
euphoria generated by the discovery of corticosteroids was rapidly tempered by the 
realization that clinicians were, in a sense, engaging in a Faustian pact between its 
impressive anti-inflammatory benefits and its potentially devastating Cushingoid side 
effects [3, 4]. 
From a cardiovascular standpoint, the propensity of glucocorticoids to produce 
hyperglycemia, hypertension, dyslipidemia, and central obesity has long produced concern 
regarding possible adverse cardiovascular events [5]. Glucocorticoids administration 
increases blood pressure in a dose dependent fashion. The mechanisms of glucocorticoids-
mediated hypertension are incompletely understood but appear to be principally related to 
increased peripheral vascular resistance rather than to mineralocorticoid receptor mediated 
effects of increased sodium retention and plasma volume expansion [6].  Dyslipidemia in 
the context of long term glucocorticoids use is characterized by increased total cholesterol, 
low density lipoprotein cholesterol, and triglycerides. Corticosteroid treatment increases the 
risk of glucose intolerance in patients without known diabetes and is associated with 
deterioration of glycaemic control in diabetic patients [7]. Glucocorticoids treatment 
therefore contributes to the exacerbation of a cluster of cardiovascular risk factors that are 
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central to the metabolic syndrome. However, as inflammation plays a central role in the 
pathogenesis of atherosclerosis [8], it is also possible that glucocorticoids may exert some 
anti-atherosclerotic effects.  
There was a significant association between ever use of oral glucocorticoids and any 
cardiovascular or cerebrovascular outcome. The association was stronger for current use of 
oral glucocorticoids than for recent or past use. Among current users, the highest odds 
ratios were observed in the group with the highest average daily dose, although the dose–
response relation was not continuous. Current use was associated with an increased risk of 
heart failure, which was consistent between patients with rheumatoid arthritis, patients with 
chronic obstructive pulmonary disease, and patients without either of the two conditions. 
Also, current use was associated with a smaller increased risk of ischaemic heart disease [9]. 
RA population has an increased cardio -vascular mortality and premature death rate, but 
why does these patients have a higher incidence of atherosclerosis? There are several factors 
which are known risks in the development of atherosclerosis. Steroids may play a role in the 
increased mortality from vascular disease. Some reports have suggested that prolonged 
treatment with steroids accelerates the development of atherosclerosis. Steroids have 
atherogenic properties that are known to enhance the development of atherosclerosis and 
they induce vascular injury. In addition, they produce a state of hypercoagulability. In 
Moreland and O’Dell study, they found an increased atherosclerotic burden in the patients 
who were on long-term steroids. This suggests that steroid treatment may be a contributor 
to the higher rate of atherosclerosis seen in them [10]. Del Rincón et al. studied the carotid 
and lower-limb arteries in a sample of RA patients, and found that the extent of cumulative 
glucocorticoids dose was significantly associated with arterial incompressibility. This 
association displayed a gradient in which the proportion of incompressible arteries 
increased with higher glucocorticoids exposure. This pattern was independent of age at RA 
onset, sex, disease duration, CV risk factors, and manifestations of RA [11]. 
2. Historical background 
Calcification of the arterial atheroma occurs in the coronary tree as it does in the remainder 
of the arterial tree. Such calcified coronary arteries are occasionally noted on routine chest 
radiographs but are difficult to distinguish from normal mediastinal structures and are 
confused with calcification in the chest wall, lungs, or other intracardiac structures [12]. 
Calcification of the coronary arteries is a common autopsy finding and is generally present 
in 80 to 90% of post-mortem studies. Despite this common pathologic finding, description of 
coronary calcification was rare until the work of Lenk [13] in 1927, who noted calcification of 
the left coronary artery on a posteroanterior chest radiograph in a 61-year-old male with left 
ventricular aneurysm. In 1964 Beadenkopf et al. [14] reported their findings in 904 
consecutive autopsies; their results indicated that as the number of coronary arteries with 
calcification increased, coronary artery wall thickness increased. Tampas and Soule [15] in 
1965 using radiographs in 1097 patients over the age of 40 found an incidence of 15% 
coronary calcification with a male to female ratio of 3 to 2 that was associated with 
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increasing age.  They suggested that coronary calcification might be an alarm signal of 
potential ischemic heart disease. Currently, it is generally recognized that the incidence of 
Coronary artery disease (CAD) was greater in patients with coronary calcification and 
atherosclerosis than in those without calcification [16].  
3. Value of assessment of preclinical atherosclerosis 
The presence of preclinical atherosclerosis increases global cardiovascular risk; therefore, it 
can be considered an emerging determinant in assessing such a risk. Single or multiple risk 
factors increase cardiovascular risk in an exponential manner, meanwhile the presence of 
one or more risk factors for atherosclerosis is associated with the development of 
cardiovascular disease. A specific issue is defined as risk factor when it is possible, on the basis of a 
strong statistical association, to relate it to the incidence of new cases of disease and if it is clinically 
demonstrated that new disease cases can be reduced by correcting the same risk factor.  
Atherosclerosis is defined as a progressive structural remodeling of a vessel wall towards 
definitive plaque formation and possible related complications. According to new data, the 
disease begins as an endothelium functional disorder [dysfunction] inducing loss of 
vascular homeostasis and related functional reserve that initially can become clinically 
evident only in conditions in which there is a need to increase tissue metabolic requirements 
(as for instance effort Angina, transient Ischemic Attack, intermittent Claudication) while, 
after more time, they can become symptomatic at rest because even basal perfusion [blood 
flow] is impaired (acute coronary syndrome, stroke, critical leg ischemia, and even 
cardiovascular death) [12].  
Coronary atherosclerosis is the leading cause of death in industrialized western countries. In 
up to 50% of its victims the first manifestation of CAD is sudden death or acute myocardial 
infarction. The cost of lost human value and approximate dollars spent ($90 billion 
annually) due to coronary artery disease in the western society is of great concern and is the 
reason for increased efforts for its prevention and its consequences as well. The detection of 
CAD in its asymptomatic stage is highly desirable because it is an increasingly treatable 
disease, but till now it has been hindered by the lack of sensitive and specific tests [13]. 
4. Methodology of assessment 
4.1. Clinical background and limitations 
In evaluating atherosclerosis the following demographic and clinical data are needed; sex, 
age, cigarette smoking, alcohol consumption, physical activity and life style, socioeconomic 
status, previous diseases, family history, BMI, WHR [waist to hip ratio] and blood pressure 
assessments in the standard way.  
Chronic subclinical inflammation is thought to be part of the metabolic syndrome [MetSyn]. 
The latter is characterized by a clustering of atherosclerotic CVD risk factors. The WHO 
definition of MetSyn [14] requires the presence of insulin resistance plus 2 other of central 
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obesity, hypertension, or dyslipidemia. Insulin resistance is thought to be the most 
prominent pathophysiological process underlying MetSyn. Recent studies of coronary artery 
calcification (CAC) in asymptomatic samples have shown an association of MetSyn and 
insulin resistance with the burden of coronary atherosclerosis [13]. Lakka et al. [15] found a 2- 
to 4-fold increased risk of cardiovascular death with MetSyn in a sample of 1209 Finnish men 
free from diabetes and CVD at baseline. MetSyn predicted atherosclerosis progression and 
CVD events in 888 subjects in the Bruneck study, whereas most individual components of the 
syndrome were not significantly associated with CVD out-comes [16] supporting the concept 
that MetSyn provides information that is “more than the sum of its parts.”[17].  
4.2. Laboratory methods 
In more than 15 large prospective studies, C-reactive protein (CRP) has emerged as an 
independent predictor of an incident cardiovascular event in initially healthy subjects and 
outcome after acute coronary syndrome [18]. More importantly, its high levels have been 
demonstrated to be an even stronger predictor of cardiovascular events than LDL 
cholesterol levels. CRP represents only one of several new inflammatory biomarkers to be 
associated, independent of lipid profile, with future cardiovascular events. Among these, 
serum amyloid A (SAA), soluble vascular cell adhesion molecule-1 (VCAM-1), soluble 
intercellular adhesion molecule 1 (ICAM-1), lipoprotein associated phospholipase A2 (Lp-
PLA2), homocysteine and monocyte chemoattractant protein-1 (MCP-1) are the best 
characterized. Interestingly, from the most recent epidemiological trials, evidence has 
consistently emerged that these biomarkers are independent from cholesterol levels, but also 
unrelated to each other. For instance, in healthy middle-aged men, CRP levels were found to 
correlate only marginally to Lp-PLA2 and MCP-1. The direct evidence that inflammatory 
biomarkers contribute to atherogenesis would be validated from the utilization of novel 
specific inhibitors for each of the soluble molecules which should prevent atherogenesis and 
coronary artery disease [18]. 
4.3. Sonographic modalities 
Atherosclerosis is a chronic inflammatory disorder that often progresses silently for decades 
before becoming clinically evident. In this section we will preview sonographic noninvasive 
imaging of the vascular changes that occur in the atherosclerosis disease process including 
assessment of its inflammatory component. Because inflammation participates in plaque 
initiation and progression, a method capable of imaging the extent of vascular inflammation 
could potentially provide powerful predictive information on both early disease presence 
and future risk for disease progression.  
4.3.1. Intima-Media Thickness (IMT) or Asymptomatic Carotid Plaque (ACP) 
Echocolordoppler scanning evaluation of the carotid wall is a non invasive, low cost, and 
highly reproducible procedure even if, like most parts of the echographic analysis, it is 
strongly operator dependent. The Doppler mode permits the visualization of vessels and an 
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evaluation of flow disturbance that helps to quantify stenosis severity. It measures the IMT 
and size and number of atheromatous plaques.  According to the European Society of 
Cardiology; 2007-Guidelines on the Management of arterial Hypertension, normal IMT is 
the distance between the media-adventitia and the intima-media interfaces and is 
interpreted as follows: 
 under 0,9 mm of the entire vascular wall;  normal  
 between 0.9 and 1.5 mm is an increased IMT,  
 While all conditions in which it is greater than 1.5 mm can be considered an ACP.  
Increased IMT (or ACP) is related to the presence, number, intensity and duration of 
atherosclerosis risk factors as well as endothelial dysfunction [24, 25]. Also, IMT is a potent 
and independent predictor of future cerebro- and cardiovascular events, as proven by 
several studies (Finnish, American Rotterdam groups) [17].  
4.3.2. Ankle Brachial Pressure Index (ABI) 
Normally, ankle systolic arterial pressure (posterior or anterior tibial artery) is just a little 
higher than brachial pressure measurements so that their ratio always is always > 1.0. This 
parameter is called the Ankle-Brachial pressure Index (ABI) and can reflect altered pressure 
values. It is reduced < 0.90 if atherosclerosis induced arterial system impairment is present; 
hence the patient is considered to have an asymptomatic peripheral artery disease. It is a 
simple, non-expensive procedure and can also be practiced by general practitioners [17]. 
Several population trials evidenced an important correlation between decreased ABI, 
carotid or coronary atherosclerosis and future cardiac or cerebrovascular events (27). 
4.3.3. Endothelial function evaluation 
A new, non-invasive technique was introduced to evaluate brachial artery flow-mediated 
dilatation (FMD). The evaluation through a sonographic assessment of brachial artery in 
basal condition and after 5 minutes of occlusion using pneumonic cuff (250 mm Hg) 
determined a reactive hyperemia and therefore, FMD. A low FMD is a marker of multifocal 
atherosclerosis and severity of the disease where the progressive reduction of FMD is 
associated with more extensive coronary tree involvement and future cardiovascular events 
[28, 29].  
4.3.4. Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1 (VCAM-1) 
VCAM-1 is expressed by activated endothelial cells and participates in leukocyte rolling and 
adhesion primarily by interacting with its counterligand VLA-4 (α4 β1) on monocytes and 
lymphocytes. VCAM-1 expression on the vessel endothelial surface or the underlying vasa 
vasorum plays an important role in atherosclerotic plaque development by monocyte and T-
lymphocyte recruitment. It is an ideal target for molecular imaging because there is little 
constitutive expression and its upregulation occurs at the earliest stages of atherogenesis. It 
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was hypothesized that molecular imaging with targeted contrast enhanced ultrasound [CEU] 
could be used to evaluate the degree of vascular inflammation in atherosclerosis. CEU have 
multiple practical considerations; low cost, short duration [10 Minutes], good sensitivity and 
balance between spatial resolution and sensitivity for targeted contrast agent detection. It 
can potentially be useful in the early diagnosis of atherosclerosis and in monitoring the 
efficacy of therapeutic interventions. 
4.4. Radiological modalities 
4.4.1. Fluoroscopy  
The detection of coronary calcification on chest films is not easy and the accuracy is only 
42% compared with fluoroscopy, which itself is not sensitive. Fluoroscopy has frequently 
been used to detect calcification in the coronary arteries [31]. Data from the Duke registry of 
800 patients by Margolis et al. [32] showed that patients with fluoroscopic evidence of 
calcium in the coronary arterial tree had a remarkably high prevalence of significant disease 
(94%). Only 6% of patients with coronary calcification had normal coronary angiograms. 
Among those without demonstrable calcification, 87% survived for more than 5 years 
compared to 58% with coronary calcification. Hence the latter implies a greater risk of future 
cardiac events. Fluoroscopy is widely available but it has several disadvantages [18]: 
1. Although it can detect moderate to large calcifications; its ability to identify small 
calcifications is low. 
2. Fluoroscopic detection of calcification is dependent on the skill and experience of the 
operator as well as the number of views studied.  
3. Other important factors include variability of the equipment, patient’s body habitus, 
and calcifications in other structures such as valves and vertebrae and overlying 
anatomic structures.  
4. Finally with fluoroscopy, quantification of calcium is not possible and film 
documentation is not commonly obtained. 
4.4.2. Computed tomography (CT)  
Conventional CT is extremely sensitive in detecting vascular calcification. CT showed 50% 
more calcified vessels than did fluoroscopy. Its limitations are slow scan times resulting in 
motion artifacts, breathing misregistration, and inability to quantify amount of plaque. 
Helical CT has considerably faster scan times than conventional CT and overlapping sections 
improves calcium detection. Double-helix CT scanners  appear to be more sensitive and now 
termed electron beam (EBCT) to distinguish them from conventional CT scanners. 
Only EBCT can quantitate the amount or volume of calcium. The absence of calcific deposits 
on an EBCT scan implies the absence of significant angiographic coronary narrowing; 
however, it does not imply the absence of atherosclerosis, including unstable plaque. One of 
the most appealing features of EBCT is the potential to detect progression or regression of 
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coronary atherosclerotic disease non-invasively and quantification with the use of calcium-
volume score. Although the ACC/AHA [American College of Cardiology (ACC) and the 
American Heart Association (AHA)] guidelines affirm the strong negative predictive value of 
a normal EBCT they are not supportive for its widespread use in asymptomatic patients [18]. 
4.4.3. Magnetic Resonance Imaging [MRI] 
Imaging techniques are needed that allow earlier and more refined diagnosis, guide targeted 
treatment in individual patients and monitor response to that treatment. MRI is well-suited 
to these tasks as it can provide anatomical, structural, and functional data of the arterial 
wall. Its capabilities are further enhanced by the use of a range of increasingly sophisticated 
contrast agents that target specific molecules, cells, and biological processes. Currently, it is 
considered to identify biologically relevant targets involved in the pathogenesis of 
atherosclerosis along its different stages [33]. 
For assessment of lesions that encroach on the vessel lumen inducing ischemia as in angina; 
angiography provides excellent resolution for the affected vascular territory with possible 
therapeutic intervention. However, atherosclerosis commonly develops within the walls of 
arteries without impinging on the vessel lumen; even established disease can be concealed 
from lumenographic methods. Unfortunately, even these non-stenotic lesions can rupture or 
erode precipitating intra-arterial thrombosis and acute ischemic events.  
Distinct from alternative imaging modalities, MRI can provide data on a large range of 
vascular parameters that includes measures of vascular physiology (compliance, pulse wave 
velocity, and flow-mediated vasodilatation), cellular imaging, molecular imaging [adhesion 
molecule expression (VCAM-1), fibrin and platelets targeting] and functional anatomical 
data such as wall sheer stresses and density of neovascularization [33]. 
4.5. Radionuclide evaluation 
4.5.1. Tc-99m sestamibi lower extremity muscle scan 
Amin et al. [34] stated that Tc-99m sestamibi lower extremity muscle scan is a technique that 
can be effectively used to diagnose preclinical atherosclerosis in rheumatoid arthritis disease 
by measuring the so called perfusion reserve [PR]. They reported that it has a place as a 
screening tool considering the fact; whenever the diagnosis, the better it is the result, 
however, it could be used for detecting preclinical atherosclerosis even in apparently 
healthy subjects. 
4.5.2. Technique 
Prior to the administration of Tc-99m sestamibi for measurement of PR in lower limbs, each 
subject moved her right foot to produce maximal dorsal and plantar flexion 30–40 times in 
the sitting position (exercising side). 185 mBq of Tc-99m sestamibi was injected through 
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intravenous line at least 10 sec before exercise termination. Posterior images of each calf 
were obtained 10 min post-injection. The processing phase was carried out by drawing 
symmetrical and equal regions of interest (ROI) over both exercising and resting calves. The 
total counts (Cts) in each (ROI) were obtained through a closed program inherent to the 
computer system [figure 1]. The percentage of increase of Cts in the exercising right calf was 
calculated, and the percentile increase obtained was considered as the perfusion reserve 
using the following formula [normal PR is approx. 50%]: 
 
Figure 1. Tc-99m sestamibi muscle scans of an RA patient (PR 29.4%) [Left panel] and a control subject 
(PR 85%) [Right panel] 
4.5.3. Myocardial sestaMIBI Gated-SPECT 
Also, in our center a study was designed to evaluate usefulness of Dipyridamole 
pharmacological stress test in conjunction with Tc-99m sestamibi Gated-SPECT to screen the 
prevalence of subclinical coronary vascular dysfunction [SCED] in asymptomatic Egyptian 
Behçet’s disease patients and to identify those at higher risk for the presence of such 
abnormalities as a predictor for preclinical atherosclerosis [data are not published yet]. 
Dipyridamole is an indirect coronary vasodilator that works by increasing intravascular 
adenosine through inhibition of phosphodiesterase that prohibits reuptake of endogenously 
produced adenosine into endothelial and red blood cells leading to arteriolar vasodilatation. 
This increases coronary arterial flow to approximately three times resting values in healthy 
endothelial state, however it is attenuated in diseased coronary arteries that cannot further 
dilate in response to adenosine. So, Dipyridamole infusion produces relative flow 
heterogeneity throughout coronary arteries, resulting in relatively more coronary blood 
flow in healthy arteries compared with the diseased-arteries inducing ischemia via a 
“coronary steal phenomenon” with subsequent perfusion defects ± abnormal left ventricular 
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wall motion during radionuclide imaging. Hence, we used Dipyridamole stress in 
conjunction with Tc-99m sestamibi Gated-SPECT as a screening tool for SCED [Figure 2 and 
3].  
 
Figure 2. A 35-year-old male with stress induced reduced flow in LAD [anterior wall] and RCA 
vascular territories [inferior wall] with Complete recovery in the rest phase Coronary angiography was 
normal; [Stress; Upper row and Rest; Lower row- Short axis slices] 
 
Figure 3. A 33-year-old negative Case for SCED [Stress; Upper row and Rest; Lower row-Short axis 
slices] 
5. Special consideration  
5.1. Premature lower limb atherosclerosis  
Symptomatic lower extremity arterial occlusive disease in young adults is presumably rare 
provided that atherosclerosis is a natural consequence of ageing process. Several factors 
contribute to the “neglect” of premature lower extremity atherosclerosis (PLEA) among 
young population in clinical practice; including low public health awareness of this 
pathology, absence of large-scale epidemiologic studies, and overall low index of suspicion 
for vascular etiology of effort-induced lower extremity symptoms. A number of small 
clinical studies published in the last decade have strongly suggested that PLEA is the major 
cause for peripheral arterial disease (PAD) in young patients [35]. 
Levy report in 2002 identified 3 major clinical presentations of PLEA; the majority of 
patients had typical symptoms of effort-induced claudication, frequently misdiagnosed and 
attributed to arthritides, muscle spasms, and trauma. Approximately 20-25% present with 
“blue toe syndrome” caused by atheromatous embolization, most frequently originating 
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from a segmental aortoiliac atherosclerotic lesion. The rest of patients presents with rapidly 
progressive symptoms of limb-threatening ischemia secondary to atherothrombosis. Also, 
they observed that many younger patients with isolated aortoiliac atherosclerotic disease 
had prolonged lower back pain on ambulation involving the spinal muscles who have been 
treated for several years for chronic low back pain by orthopedic surgeons, or 
neurosurgeons and some of them even had “unsuccessful” laminectomies before the 
diagnosis of PAD. In PLEA patients, clinical atherosclerotic disease was present in more 
than one anatomic location in approximately 60% including the coronary tree. Noninvasive 
studies are a mainstay of the PLEA diagnosis including ABI measurement and standardized 
lower extremity treadmill testing that has been developed to assess hyperemic blood flow 
response to exercise with repeat ABIs compared to the resting ABI with pulse-wave 
recordings. Also, Tc-99m sestamibi lower extremity muscle scan is suggested as a diagnostic 
test in PLEA patients [35]. 
6. Summary and conclusions 
In summary, improved understanding of atherogenesis allowed the identification of a large 
number of molecules and processes. This will provide functional insights to aid diagnosis 
and to guide treatment with the introduction of new molecular imaging approaches that 
hold much promise for translation to the clinical practice. In fact, inflammatory biomarkers 
and imaging will combine structural and functional information to provide a 
comprehensive evaluation of vascular status at an early stage; hoping to be reversible. 
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